CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Vosoughi, Tina; Bagheri, Marziye; Hosseinzadeh, Mehran; Ehsanpour, Ali; Davari, Nader; Saki, Najmaldin

doi:10.1002/jcp.28724

Cited by 11 publications

(21 citation statements)

References 171 publications

(251 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both of them can predict TTFT in the Binet 0 stage [35]. CD38 positivity, which is associated with other unfavorable factors such as higher s-β2M level and high-risk karyotypes, predicts the resistance of treatment, hepatomegaly and shorter survival [36,37]. ZAP70 expression is associated with disease progression and is a predictor of Ritcher's syndrome (RS) [38,39].…”

Section: Immunophenotypic Markersmentioning

confidence: 99%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia with high heterogeneity in the western world. Thus, investigators identified a number of prognostic biomarkers and scoring systems to guide treatment decisions and validated them in the context of immunochemotherapy. A better understanding of prognostic biomarkers, including serum markers, flow cytometry outcomes, IGHV mutation status, microRNAs, chromosome aberrations and gene mutations, have contributed to prognosis in CLL. Del17p/ TP53 mutation, NOTCH1 mutation, CD49d, IGHV mutation status, complex karyotypes and microRNAs were reported to be of predictive values to guide clinical decisions. Based on the biomarkers above, classic prognostic models, such as the Rai and Binet staging systems, MDACC nomogram, GCLLSG model and CLL-IPI, were developed to improve risk stratification and tailor treatment intensity. Considering the presence of novel agents, many investigators validated the conventional prognostic biomarkers in the setting of novel agents and only TP53 mutation status/del 17p and CD49d expression were reported to be of prognostic value. Whether other prognostic indicators and models can be used in the context of novel agents, further studies are required.

show abstract

Section: Immunophenotypic Markersmentioning

confidence: 99%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

show abstract

“…It seems that assessing clinical course of the CLL disease combined with molecular and biological factors can predict disease progression and patient's survival (1,5). In this regard, we investigated the changes in the expressions of different immunophenotypic markers in CLL patients to explore prognostic value of these markers in these patients.…”

Section: Discussionmentioning

confidence: 99%

“…Chronic lymphocytic leukemia (CLL) is one of the most common types of adult leukemia that presents with the abnormal clonal accumulation of B lymphocytes in peripheral blood (PB), bone marrow (BM), or tissues (1,2,3).…”

Section: Introductionmentioning

confidence: 99%

“…As interleukin-2 (IL-2) receptor alpha chain, CD25 can be expressed in 30-50% of CLL patients. (1,8). CD38, a type 2 trans-membrane glycoprotein, participates in many cellular activities, including cell adhesion, signal transduction, and calcium regulation.…”

Section: Introductionmentioning

confidence: 99%

“…CD38, a type 2 trans-membrane glycoprotein, participates in many cellular activities, including cell adhesion, signal transduction, and calcium regulation. Some studies showed that the expression of CD38 in CLL cells is associated with resistance to treatment, shorter survival, and aggressive clinical outcomes (1,9) and high expression of CD38 can act as an adverse prognostic factor (10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Immunophenotypic Markers and Clinico-Hematological Profile in Chronic Lymphocytic Leukemia: Implications for Prognosis

Bagheri

Vosoughi

Hosseinzadeh

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Objective: Chronic lymphocytic leukemia (CLL) is an adult leukemia presented with clonal accumulation of lymphocytes. Immunophenotypic changes can be effective in predicting clinical course, the survival of patients, and determining first-line treatment. This is a study of the association between immunophenotypic markers with complete blood cell count (CBC) values and clinical parameters.Results: Peripheral blood samples were collected from 35 newly diagnosed CLL patients. The expression of immunophenotypic markers and CBC were evaluated. Platelet counts and hemoglobin concentration had a significant, inverse association with Rai staging, modified Rai staging, Binet staging systems (all p< 0.001 in both parameters), and splenomegaly (p = 0.001 and 0.007, respectively). The platelet/lymphocyte ratio (PLR) had a significant, inverse ‎association with Rai staging (p = 0.014), modified Rai staging (p = 0.024), Binet staging systems (p = 0.027), and splenomegaly (p = 0.033). However, CD38, CD25, and double-positive CD56/CD117 expression, group3 of innate lymphocyte cells (ILC3s), had no significant association with clinical parameters. In regression analysis, that ILC3s has an inverse correlation with neutrophil/lymphocyte ratio (r = -0.340, p = 0.046). Given that there is an inverse ‎association between PLR and advanced clinical stages, it seems that PLR may have prognostic value in CLL.

show abstract

Multiple omics levels of chronic lymphocytic leukemia

Turk,

Čeh,

Calin

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by the proliferation of functionally mature but incompetent B cells. It is the most prevalent type of leukemia in Western populations, accounting for approximately 25% of new leukemia cases. While recent advances, such as ibrutinib and venetoclax treatment have improved patient outlook, aggressive forms of CLL such as Richter transformation still pose a significant challenge. This discrepancy may be due to the heterogeneity of factors contributing to CLL development at multiple -omics levels. However, information on the omics of CLL is fragmented, hindering multi-omics-based research into potential treatment options. To address this, we aggregated and presented a selection of important aspects of various omics levels of the disease in this review. The purpose of the present literature analysis is to portray examples of CLL studies from different omics levels, including genomics, epigenomics, transcriptomics, epitranscriptomics, proteomics, epiproteomics, metabolomics, glycomics and lipidomics, as well as those identified by multi-omics approaches. The review includes the list of 102 CLL-associated genes with relevant genomics information. While single-omics studies yield substantial and useful data, they omit a significant level of complex biological interplay present in the disease. As multi-omics studies integrate several different layers of data, they may be better suited for complex diseases such as CLL and have thus far yielded promising results. Future multi-omics studies may assist clinicians in improved treatment choices based on CLL subtypes as well as allow the identification of novel biomarkers and targets for treatments.

show abstract

CD markers variations in chronic lymphocytic leukemia: New insights into prognosis

Cited by 11 publications

References 171 publications

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

Evaluation of Immunophenotypic Markers and Clinico-Hematological Profile in Chronic Lymphocytic Leukemia: Implications for Prognosis

Multiple omics levels of chronic lymphocytic leukemia

Contact Info

Product

Resources

About